- Home
- DBD vs CLDX Comparison
DBD vs CLDX Comparison
Compare DBD & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- CLDX
- Stock Information
- Founded
- DBD 1859
- CLDX 1983
- Country
- DBD United States
- CLDX United States
- Employees
- DBD N/A
- CLDX N/A
- Industry
- DBD EDP Services
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DBD Technology
- CLDX Health Care
- Exchange
- DBD Nasdaq
- CLDX Nasdaq
- Market Cap
- DBD 1.8B
- CLDX 1.8B
- IPO Year
- DBD N/A
- CLDX 2008
- Fundamental
- Price
- DBD $47.22
- CLDX $26.04
- Analyst Decision
- DBD Strong Buy
- CLDX Buy
- Analyst Count
- DBD 2
- CLDX 8
- Target Price
- DBD $57.50
- CLDX $64.83
- AVG Volume (30 Days)
- DBD 137.6K
- CLDX 992.8K
- Earning Date
- DBD 02-12-2025
- CLDX 11-06-2024
- Dividend Yield
- DBD N/A
- CLDX N/A
- EPS Growth
- DBD N/A
- CLDX N/A
- EPS
- DBD 0.00
- CLDX N/A
- Revenue
- DBD $3,799,000,000.00
- CLDX $9,976,000.00
- Revenue This Year
- DBD $0.73
- CLDX N/A
- Revenue Next Year
- DBD $1.58
- CLDX N/A
- P/E Ratio
- DBD $15,220.39
- CLDX N/A
- Revenue Growth
- DBD 2.88
- CLDX 128.55
- 52 Week Low
- DBD $27.47
- CLDX $22.93
- 52 Week High
- DBD $51.81
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- DBD 54.38
- CLDX 46.00
- Support Level
- DBD $46.32
- CLDX $24.48
- Resistance Level
- DBD $49.08
- CLDX $26.66
- Average True Range (ATR)
- DBD 1.48
- CLDX 1.24
- MACD
- DBD 0.09
- CLDX 0.04
- Stochastic Oscillator
- DBD 33.41
- CLDX 37.41
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are banking which offers integrated solutions for financial institutions and retail which offers solutions, software, and services which improve the checkout process for retailers.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.